AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04619290
Drug: Sublingual Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
Trial: NCT00258297
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03773068
Drug: BAY1817080 - Formulation A
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A
Trial: NCT01526928
Drug: Rociletinib
RxNorm normalized name: rociletinib
DrugBank: Rociletinib (DB11907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
Trial: NCT01526928
Drug: Rociletinib
RxNorm normalized name: rociletinib
DrugBank: Rociletinib (DB11907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
Trial: NCT01526928
Drug: Rociletinib
RxNorm normalized name: rociletinib
DrugBank: Rociletinib (DB11907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily
Trial: NCT01526928
Drug: Rociletinib
RxNorm normalized name: rociletinib
DrugBank: Rociletinib (DB11907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily
Trial: NCT01526928
Drug: Rociletinib
RxNorm normalized name: rociletinib
DrugBank: Rociletinib (DB11907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily
Trial: NCT01526928
Drug: Rociletinib
RxNorm normalized name: rociletinib
DrugBank: Rociletinib (DB11907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily
Trial: NCT00252421
Drug: Nitroglycerin ointment 15 mg/day daily for 24 month
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment 15 mg/day applied daily for 24 mth
Trial: NCT04418999
Drug: dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental
Trial: NCT04418999
Drug: Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
RxNorm normalized name: Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT00189098
Drug: Sulfamethoxazole-trimethoprim
RxNorm normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 mg/kg, two times a day
Trial: NCT00593866
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
Trial: NCT03446872
Drug: ONIVYDE
RxNorm normalized name: Onivyde
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: irinotecan liposome injection
Trial: NCT03446872
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a nucleoside metabolic inhibitor
Trial: NCT00398086
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by intravenous infusion over 30 minutes.
Trial: NCT00539734
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose of 0.5 mg ranibizumab injected intravitreally.
Trial: NCT00355095
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous daily 3.3 \*10\^4 Units, duration 3 days
Trial: NCT03101930
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous liraglutide daily
Trial: NCT03101930
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral sitagliptin daily
Trial: NCT00398086
Drug: Albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion over 30 minutes.
Trial: NCT01600885
Drug: Guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
Trial: NCT03101930
Drug: Exendin (9-39)
RxNorm normalized name: EXENDIN (9-39)
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
Trial: NCT02399215
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01056601
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
Trial: NCT01056601
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
Trial: NCT02908945
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
Trial: NCT02180464
Drug: control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02319200
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months
Trial: NCT03429972
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
Trial: NCT03372473
Drug: Montelukast mixed with Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast 5mg mixed with Loratadine 5mg, one dose per day
Trial: NCT03372473
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast 5mg
Trial: NCT01605773
Drug: repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose individually adjusted and conducted according to labeling
Trial: NCT02073227
Drug: Canagliflozin, 300 mg
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
Trial: NCT02073227
Drug: Metformin XR, 500 mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
Trial: NCT01605773
Drug: glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose individually adjusted and conducted according to labeling
Trial: NCT00436722
Drug: ATG (Fresenius Biotech)
RxNorm normalized name: ATGAM
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG-Fresenius 9 mg/kg at induction
Trial: NCT00491751
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 40 or 80 mg/day
Trial: NCT02268149
Drug: BIIL 284 BS
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02268149
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01084707
Drug: Oral Nicotine
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Nicotine either self-administered or provided by study personnel within 12 hours
Trial: NCT01084707
Drug: Nicotine Lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
Trial: NCT01084707
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
Trial: NCT00010725
Drug: MAK
RxNorm normalized name: Maki
DrugBank: Vilamakitug (DB18978)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00010725
Drug: Vitamin Supplements
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03617172
Drug: Misoprostol 100Mcg Tab
RxNorm normalized name: MISOPROSTOL 100MCG TAB
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 100mcg capsules twice per day
Trial: NCT01888744
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01888744
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01888744
Drug: Human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: induction of final oocyte maturation
Trial: NCT01888744
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02918591
Drug: Empagliflozine
RxNorm normalized name: Empagliflozine
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
Trial: NCT02538744
Drug: Doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
Trial: NCT02538744
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 \[placebo\], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
Trial: NCT02538744
Drug: cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
Trial: NCT00124384
Drug: modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05963334
Drug: Carboplatin/paclitaxel
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
Trial: NCT00472108
Drug: Metvix cream
RxNorm normalized name: Metvixia
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02258815
Drug: ch14.18/CHO
RxNorm normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year.
Trial: NCT01497002
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
Trial: NCT00976937
Drug: Lixisenatide (AVE0010)
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Trial: NCT00976937
Drug: Lixisenatide Placebo
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Trial: NCT00976937
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally once a day in the morning with or without food at approximately the same time each day.
Trial: NCT00976937
Drug: Sitagliptin Placebo
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally once a day in the morning with or without food at approximately the same time each day.
Trial: NCT00976937
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
Trial: NCT00951379
Drug: Pioglitazone hydrochloride
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
Trial: NCT01281163
Drug: Akt Inhibitor MK2206
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00716963
Drug: Fluticasone propionate (Flovent Diskus) 250 mcg
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Flovent Diskus 250 mcg
Trial: NCT00716963
Drug: budesonide 400 mcg
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide 400 mcg
Trial: NCT01281163
Drug: Lapatinib Ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01472640
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.8 mg sc QOD
Trial: NCT02336386
Drug: CDD
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT02336386
Drug: CDD Plus Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy plus Proteasome Inhibitors
Trial: NCT00686504
Drug: AZD2066
RxNorm normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of oral dose, 3 times per subject
Trial: NCT03531918
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03531918
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03531918
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT03531918
Drug: Mitoxantrone Hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04385680
Drug: Chlorhexidine Gluconate vaginal solution 0.05%
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preoperative vaginal preparation
Trial: NCT00110929
Drug: AMG 073
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02650791
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01917617
Drug: Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively.
Trial: NCT01917617
Drug: Gemcitabine , Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more.
Trial: NCT00095693
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00224445
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
Trial: NCT00224445
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
Trial: NCT00224445
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir 100 mg capsule administered orally QD
Trial: NCT01692483
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Trial: NCT01315873
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment.
Trial: NCT01315873
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment.
Trial: NCT01692483
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone or prednisolone 5 mg tablet taken orally twice daily
Trial: NCT01850511
Drug: Application of oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.